Hydrocortisone succinate

Generic Name: Hydrocortisone succinate

Brand Names: Solu-cortef

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₄O_₈

CAS Number: 2203-97-6

Unique Ingredient Identifier: IHV1VP592V

Associated Conditions: Acquired hemolytic anemias, Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia, Idiopathic Nephrotic Syndrome, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Mycosis Fungoides (MF), Ocular Inflammatory Disease, Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Proteinuria, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Severe Allergic Reactions, Severe Erythema multiforme, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1

Recruiting

Conditions: Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Myelodysplastic Syndrome
Recurrent Juvenile Myelomonocytic Leukemia
Refractory Childhood Acute Myeloid Leukemia
Refractory Childhood Myelodysplastic Syndrome
Refractory Juvenile Myelomonocytic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Procedure: Echocardiography
Drug: Fludarabine
Drug: Hydrocortisone Sodium Succinate
Biological: Imetelstat
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Methotrexate

First Posted Date: 2024-02-08

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 36

Registration Number: NCT06247787

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 10 locations

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Calaspargase Pegol
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Prednisolone
Drug: Prednisone
Drug: Revumenib
Drug: Vincristine Sulfate

First Posted Date: 2023-03-09

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 78

Registration Number: NCT05761171

Locations: 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸
Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 62 locations

Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone.

Phase 2

Recruiting

Conditions: Oral Pyogenic Granuloma

Interventions: Drug: Solu-Cortef

First Posted Date: 2022-09-09

Last Posted Date: 2022-09-14

Lead Sponsor: Beni-Suef University

Target Recruit Count: 30

Registration Number: NCT05534334

Locations: 🇪🇬
Beni_Suef University, Banī Suwayf, Bani Suwayf, Egypt
🇪🇬
Eman Ahmed, Banī Suwayf, Benisuef, Egypt

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1

Withdrawn

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Refractory T Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent T Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Mixed Phenotype Acute Leukemia

Interventions: Drug: Anti-CD123 ADC IMGN632
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Cytarabine
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Drug: Methotrexate
Drug: Prednisolone

First Posted Date: 2022-04-11

Last Posted Date: 2023-09-01

Lead Sponsor: Children's Oncology Group

Registration Number: NCT05320380

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2

Suspended

Conditions: Down Syndrome
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Dexamethasone
Drug: Calaspargase Pegol
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Biological: Nivolumab
Drug: Mercaptopurine
Drug: Pegaspargase
Drug: Pegcrisantaspase
Drug: Vincristine Sulfate

First Posted Date: 2020-09-14

Last Posted Date: 2024-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT04546399

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States

and more 200 locations

Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)

Phase 3

Conditions: Vasoplegia
Cardiac Surgery

Interventions: Drug: Saline
Drug: hydrocortisone sodium succinate

First Posted Date: 2020-03-10

Last Posted Date: 2020-03-10

Lead Sponsor: Instituto do Coracao

Target Recruit Count: 140

Registration Number: NCT04301479

Locations: 🇧🇷
Incor - Heart Institute - University of Sao Paulo, Sao Paulo, Brazil

Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis

Phase 4

Conditions: Ulcerative Colitis, Unspecified

Interventions: Drug: Mesalazine with hydrocortisone sodium succinate
Drug: Mesalazine
Drug: hydrocortisone sodium succinate

First Posted Date: 2017-04-12

Last Posted Date: 2017-04-12

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 528

Registration Number: NCT03110198

Locations: 🇨🇳
Xijing Digestive Disease, Xi'an, Shaanxi, China

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

First Posted Date: 2016-08-30

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5949

Registration Number: NCT02883049

Locations: 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 236 locations

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

First Posted Date: 2016-07-11

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT02828358

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 170 locations

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

First Posted Date: 2014-04-14

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 847

Registration Number: NCT02112916

Locations: 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸
UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺
Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia

and more 209 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy